
## Roger K Cady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9135448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology, 2020, 94, e1365-e1377.	1.1	236
2	Managing migraine by patient profile: role of frovatriptan. Patient Preference and Adherence, 2016, 10, 501.	1.8	6
3	Acupuncture in the Treatment of Headache: A Traditional Explanation of an Ancient Art. Headache, 2015, 55, 457-464.	3.9	13
4	Acute and Preventative Treatment of Episodic Migraine. , 2015, , 69-97.		1
5	Chronic Migraine. , 2015, , 99-122.		1
6	Longâ€Term Efficacy of a Doubleâ€Blind, Placebo ontrolled, Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the <scp>Tx</scp> 360 <sup>®</sup> Device for Treatment of Chronic Migraine. Headache, 2015, 55, 529-542.	3.9	44
7	A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. Expert Opinion on Drug Delivery, 2015, 12, 1565-1577.	5.0	20
8	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology, 2015, 84, 688-695.	1.1	219
9	The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine. Expert Opinion on Pharmacotherapy, 2015, 16, 2039-2051.	1.8	6
10	A Doubleâ€Blind, Placeboâ€Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With <scp>T</scp> x360 <sup>®</sup> as Acute Treatment for Chronic Migraine. Headache, 2015, 55, 101-116.	3.9	87
11	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder ( <scp>AVP</scp> â€825) in the Treatment of Acute Migraine (The <scp>TARGET</scp> ) Tj E <sup>-</sup>	[Qop1 1 (	).7 <b>&amp;4</b> 314 rgB
12	<scp>AVP</scp> â€825 Breathâ€Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The <scp>COMPASS</scp> Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. Headache, 2015, 55, 621-635.	3.9	44
13	An Exploratory Study of Salivary Calcitonin Geneâ€Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With Onabotulinumtoxin <scp>A</scp> in Chronic Migraine. Headache, 2014, 54, 269-277.	3.9	40
14	<scp>SumaRT</scp> / <scp>N</scp> ap vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study. Headache, 2014, 54, 67-79.	3.9	12
15	Red Flags and Comfort Signs for Ominous Secondary Headaches. Otolaryngologic Clinics of North America, 2014, 47, 289-299.	1.1	11
16	Treatment of Chronic Migraine: A 3â€Month Comparator Study of Naproxen Sodium vs <scp>SumaRT</scp> / <scp>N</scp> ap. Headache, 2014, 54, 80-93.	3.9	17
17	Ophthalmic beta blockers: treatment for acute migraine?. Missouri Medicine, 2014, 111, 292-3.	0.3	1
18	Advances in Drug Development for Acute Migraine. Drugs, 2012, 72, 2187-2205.	10.9	10

ROGER K CADY

#	Article	IF	CITATIONS
19	The Bowel and Migraine: Update on Celiac Disease and Irritable Bowel Syndrome. Current Pain and Headache Reports, 2012, 16, 278-286.	2.9	43
20	Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Preâ€Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications. Headache, 2012, 52, 749-764.	3.9	15
21	The Development of a Survey to Measure Completeness of Response to Migraine Therapy. Headache, 2012, 52, 550-572.	3.9	9
22	Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Current Medical Research and Opinion, 2011, 27, 2185-2191.	1.9	12
23	Total Migraine Freedom, a Potential Primary Endpoint to Assess Acute Treatment in Migraine: Comparison to the Current FDA Requirement Using the Complete Rizatriptan Study Database. Headache, 2011, 51, 356-368.	3.9	17
24	A Doubleâ€Blind Placeboâ€Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic <sup>TM</sup> M) in the Treatment of Migraine. Headache, 2011, 51, 1078-1086.	3.9	61
25	Multi-Center Comparison of Response to a Single Tablet of Sumatriptan 85 mg and Naproxen 500 mg vs Usual Therapy Treating Multiple Migraine Attacks as Measured by the Completeness of Response Survey. Headache, 2011, 51, 961-970.	3.9	4
26	Satisfaction With and Confidence in Needle-Free Subcutaneous Sumatriptan in Patients Currently Treated with Triptans. Headache, 2011, 51, 1202-1211.	3.9	20
27	Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine. Headache, 2011, 51, 1573-1577.	3.9	67
28	Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia, 2011, 31, 18-30.	3.9	53
29	Predictability of Future Attacks by Migraineurs: A Prospective Observational Study. Headache, 2010, 50, 1296-1305.	3.9	10
30	Changes in Salivary Prostaglandin Levels During Menstrual Migraine With Associated Dysmenorrhea. Headache, 2010, 50, 844-851.	3.9	39
31	OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. Expert Opinion on Biological Therapy, 2010, 10, 289-298.	3.1	9
32	The Future of Migraine: Beyond Just Another Pill. Mayo Clinic Proceedings, 2009, 84, 397-399.	3.0	5
33	Sinus problems as a cause of headache refractoriness and migraine chronification. Current Pain and Headache Reports, 2009, 13, 319-325.	2.9	25
34	Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Doubleâ€Blind Trial. Headache, 2009, 49, 216-226.	3.9	32
35	Predictors of Adherence to Triptans: Factors of Sustained vs Lapsed Users. Headache, 2009, 49, 386-394.	3.9	31
36	Elevated Saliva Calcitonin Geneâ€Related Peptide Levels During Acute Migraine Predict Therapeutic Response to Rizatriptan. Headache, 2009, 49, 1258-1266.	3.9	99

ROGER K CADY

#	Article	IF	CITATIONS
37	Needleâ€Free Subcutaneous Sumatriptan (Sumavelâ"¢ DoseProâ"¢): Bioequivalence and Ease of Use. Headache, 2009, 49, 1435-1444.	3.9	43
38	Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Current Medical Research and Opinion, 2009, 25, 2711-2721.	1.9	11
39	Botulinum Toxin Type A as Migraine Preventive Treatment in Patients Previously Failing Oral Prophylactic Treatment Due To Compliance Issues. Headache, 2008, 48, 900-913.	3.9	50
40	Does Early Migraine Treatment Shorten Time to Headache Peak and Reduce Its Severity?. Headache, 2008, 48, 914-920.	3.9	15
41	Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. Mayo Clinic Proceedings, 2007, 82, 61-68.	3.0	20
42	Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. Mayo Clinic Proceedings, 2007, 82, 61-68.	3.0	25
43	Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT�Early Migraine Intervention) Tj ETQq1	1 0,78431 3.9	4 rgBT /Over
44	The epidemiology and pathophysiology of migraine. Managed Care, 2007, 16, 4-9; discussion 15-7.	0.3	4
45	Salivary Levels of CGRP and VIP in Rhinosinusitis and Migraine Patients. Headache, 2006, 46, 24-33.	3.9	135
46	Efficacy of Rizatriptan 10 mg Administered Early in a Migraine Attack. Headache, 2006, 46, 914-924.	3.9	67
47	Treating Early Versus Treating Mild: Timing of Migraine Prescription Medications Among Patients With Diagnosed Migraine. Headache, 2005, 45, 538-545.	3.9	76
48	Cosensitization of pain and psychiatric comorbidity in chronic daily headache. Current Pain and Headache Reports, 2005, 9, 47-52.	2.9	34
49	Sinus Headache: A Neurology, Otolaryngology, Allergy, and Primary Care Consensus on Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 908-916.	3.0	97
50	Regulation of Calcitonin Geneâ€Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy. Headache, 2004, 44, 35-43.	3.9	479
51	Understanding the Patient With Migraine: The Evolution From Episodic Headache to Chronic Neurologic Disease. A Proposed Classification of Patients With Headache. Headache, 2004, 44, 426-435.	3.9	61
52	Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Current Medical Research and Opinion, 2004, 20, 1465-1472.	1.9	70
53	Sinus headache: a clinical conundrum. Otolaryngologic Clinics of North America, 2004, 37, 267-288.	1.1	74
54	Primary Headaches: A Convergence Hypothesis. Headache, 2002, 42, 204-216.	3.9	107

Roger K Cady

#	Article	IF	CITATIONS
55	Sinus headache or migraine?. Neurology, 2002, 58, S10-4.	1.1	124
56	A Pilot Study to Measure Cognitive Efficiency During Migraine. Headache, 2000, 40, 657-661.	3.9	62
57	Sumatriptan for the Range of Headaches in Migraine Sufferers: Results of the Spectrum Study. Headache, 2000, 40, 783-791.	3.9	215
58	Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clinical Therapeutics, 2000, 22, 1035-1048.	2.5	217
59	Sumatriptan for the Range of Headaches in Migraine Sufferers: Results of the Spectrum Study. Headache, 2000, 40, 783-791.	3.9	207
60	Treatment of Acute Migraine With Subcutaneous Sumatriptan. JAMA - Journal of the American Medical Association, 1991, 265, 2831.	7.4	248